928264-39-5

Upstream product

• 75-05-8 acetonitrile 
• 205045-49-4 3-Isopropoxy-benzoic acid ethyl ester 
• 928264-38-4 tert-butyl 2-cyano-3-(3-isopropoxyphenyl)-3-oxopropanoate 

Downstream Products

• 928264-40-8 1-(3,5-dimethylpyridin-4-yl)-3-(3-isopropoxyphenyl)-1H-pyrazol-5-amine 
• 1217089-34-3 3-(3-isopropoxyphenyl)-1H-pyrazol-5-amine 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors

Described herein is design, synthesis, and biological evaluation of novel series of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines acting as inhibitors of type 4 phosphodiesterase (PDE4) which is known as a good target for the treatment of asthma and COPD. For this purpose, structure optimization was conducted with the aid of structure-based drug design using the known X-ray crystallography. Also, biological effects of these compounds on the target enzyme were evaluated by using in vitro assays, leading to the potent and selective PDE-4 inhibitor (IC50 10 nM).

ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES

The present invention relates to anilinopyrazole compounds of formula (1) in which R3 represents an aromatic 5- or 6-membered heteroaromatic ring which is optionally fused to phenyl, said heterocycle or fused heterocycle is optionally substituted, X represents a carboxylic acid, ester or amide, or sulfonamide, and the remaining groups are as defined in the text. It also relates to pharmaceutical compositions containing these materials and, and methods for treating diabetes and related disorders using these materials.